91361-92-1

Basic information

• Product Name: (4-mercapto-phenyl)-acetic acid methyl ester
• Synonyms: (4-mercapto-phenyl)-acetic acid methyl ester
• CAS NO: 91361-92-1
• Molecular Weight: 182.243
• Mol File: 91361-92-1.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: (4-mercapto-phenyl)-acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-mercapto-phenyl)-acetic acid methyl ester(91361-92-1)
• EPA Substance Registry System: (4-mercapto-phenyl)-acetic acid methyl ester(91361-92-1)

Safety Data

• Hazardous Substances Data: 91361-92-1(Hazardous Substances Data)

Upstream product

• 101-97-3 Ethyl 2-phenylethanoate 
• 1235544-51-0 2-(4-((ethoxycarbonothioyl)thio)phenyl)acetic acid 
• 67-56-1 methanol 
• 39161-84-7 4-mercaptophenylacetic acid 
• 1197-55-3 4-aminophenylacetic acid 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 156-38-7 4-hydroxyphenylacetate 
• 104-01-8 4-Methoxyphenylacetic acid 
• 87202-52-6 (4-chlorosulfonyl-phenyl)acetic acid ethyl ester 
• 477256-87-4 (4-Dimethylthiocarbamoyloxy-phenyl)-acetic acid methyl ester 

Downstream Products

• 185802-94-2 [4-(3-Bromo-propylsulfanyl)-phenyl]-acetic acid 
• 1026579-35-0 methyl 4-(2-aminoethylthio)phenylacetate 
• 141267-15-4 methyl 4-<2-(phenylsulfonylamino)ethylthio>phenylacetate 
• 141267-17-6 methyl 4-[2-(4-methylphenylsulfonylamino)ethylthio]phenylacetate 
• 141267-19-8 methyl 4-[2-(4-fluorophenylsulfonylamino)ethylthio]phenylacetate 
• 141267-18-7 methyl 4-[2-(4-bromophenylsulfonylamino)ethylthio]phenylacetate 
• 141267-20-1 methyl 4-[2-(4-methoxyphenylsulfonylamino)ethylthio]phenylacetate 
• 141267-21-2 methyl 4-[2-(4-nitrophenylsulfonylamino)ethylthio]phenylacetate 
• 1361414-24-5 methyl 2-(4-((2,2,2-trifluoroethyl)sulfonyl)phenyl)acetate 
• 1153070-21-3 2-(4-((2,2,2-trifluoroethyl)sulfonyl)phenyl)acetic acid 
• 1363178-92-0 N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yI]-2-{4-[(2,2,2-trifluoroethyl)sulfonyl]phenyl}acetamide 
• 1363179-33-2 methyl 2-(4-(2-methoxyethylsulfonyl)phenyl)acetate 
• 1155610-14-2 2-(4-(2-methoxyethylsulfonyl)phenyl)acetic acid 
• 1363178-96-4 2-(4-{[2-(methyloxy)ethyl]sulfonyl}phenyl)-N-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]acetamide 

Relevant articles and documents

ROR [gamma]t inhibitor, preparation method and application thereof

The invention relates to the technical field of medicines, in particular to an ROR [gamma]t inhibitor, a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound, a method for preparing the pharmaceutical composition, and application of the compound or the pharmaceutical composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

TRISUBSTITUTED HETEROCYCLIC DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides trisubstituted heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; (I) in which R1, R2, R3, Ra, X, L, m and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the trisubstituted heterocyclic derivatives of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.